38 results about "Megakaryocytic cell" patented technology

The present invention discloses the signaling pathway involved in erythroid repression by iron deficiency. Further disclosed is a non-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakary-ocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.

The present invention relates to mainly one system of efficient culturing and directive inducing stem cell differentiation for culturing and proliferating megakaryocyte. The system has umbilical cord blood and marrow stem cell as seed cell, and the serum-free culture medium comprising TPO, IL-11 and heparin as the main component for megakaryocyte proliferation. The megakaryocyte preparation prepared based on the present invention contains great amount of macronucleus ancestral cells and mature megakaryocyte as well as CD34+ cells, and has the functions of treating thrombocytopenia and improving the blood-forming function after stem cell transplantation. The present invention provides novel efficient cell treating preparation for various thrombocytopenia and hemocyitopenia.

The invention discloses a therapeutic dendritic cell cancer vaccine and application thereof, and belongs to the technical field of biology. A shuttle plasmid pGBC-IRES-WSL and a recombinant adenoviruscapable of simultaneously expressing a tumor-associated antigen, a granulocyte-megakaryocyte colony stimulating factor (GM-CSF), CD40L and 4-1BBL is constructed, and human peripheral blood-derived mononuclear cells are infected with the recombinant adenovirus to obtain the therapeutic dendritic cell cancer vaccine. The cancer vaccine can play an anti-tumor role by inducing an organism to generateantigen-specific T lymphocytes so that the cancer vaccine is used for treating various blood system tumors and solid tumors.

The invention relates to the technical field of biological cell preparation, in particular to a preparation method and application of an umbilical cord mesenchymal stem cell nutrient solution. The invention aims to provide a cell nutrient solution which can well repair skin cells and has a good beautifying effect and an application method of the cell nutrient solution. According to the technical scheme, the method comprises the following steps: separating mesenchymal stem cells, culturing the stem cells, and preparing a cell nutrient solution; the mesenchymal stem cell nutrient solution obtained by the invention comprises high-concentration human umbilical cord blood mesenchymal stem cells; a supernatant of the kit contains vascular endothelial cell growth factors, basic fibroblast growth factors, epidermal growth factors, IL-6 and IL-7, megakaryocyte colony stimulating factors, tumor necrosis factors, interferon and other factors, deoxyribonucleic acid and ribonucleic acid, monocyte chemotactic proteins, intercellular adhesion molecules, active polypeptides, immune proteins IgG, IgA, IgM, IgD, IgE and the like. The repair of tissue defects can be well promoted.

The present invention discloses the signaling pathway involved erythroid repression by iron deficiency. Further disclosed is anon-toxic small-molecule compound which potently reverses the erythroid repression caused by iron deficiency. The present invention further encompasses novel compounds for inhibition of red cell production, useful, for example, in the treatment of polycythemia vera, a malignancy causing uncontrolled red cell production. These inhibitory compounds also promote megakaryocytic lineage commitment and may therefore be useful for augmentation of platelet production. The present invention further discloses isocitrate reversal of iron deprivation.

An object of the present invention is to provide a separation substrate having a high megakaryocyte blocking rate and a high platelet permeation rate, and a cell separation filter and a method for producing a platelet which use the same. The separation substrate of the present invention is a separation substrate including a porous membrane for separating a platelet from a cell suspension containing a megakaryocyte and the platelet, in which an average pore diameter of the separation substrate is 2.0 μm to 12.0 μm, and the separation substrate is formed of at least one resin selected from the group consisting of a polysulfone resin and a polyvinylidene fluoride resin.

An object of the present invention is to provide a method for more efficiently differentiating CD34⁺ cells derived from umbilical cord blood into megakaryocytic lineage cells and for generating platelets. Coculture of CD34⁺ cells derived from umbilical cord blood with immortalized stromal cells in the presence of cytokines has enabled cell proliferation up to the 100,000-fold level, which has been impossible to achieve to date.

The invention discloses an application of AMF (amifostine) in treatment of tumors with high Cyclin D1 expression. According to research, AMF inhibits tumor cell growth by inhibiting cancer gene CyclinD1 expression in a targeted manner and resists the tumors by inhibiting the CyclinD1 expression in a targeted manner, and the functions are successfully verified through megakaryocyte leukemia cell lines Dami; and AMF successfully cures mantle cell lymphoma with high Cyclin D1 expression and high leukocyte expression as characteristics in clinical practice.

The invention relates to construction of an SV40LT gene-mediated megakaryocyte model and a cell bank of megakaryocyte, belonging to the field of medical research. The construction is mainly characterized in that an SV40LTag-pcDNA3.1 (-) recombinant is constructed from T4DNA ligase, BamHI, pcDNA3.1 (-) DNA and SV40LTag DNA by virtue of conventional means; the recombinant is purified by virtue of competent escherichia coli; the recombinant is introduced into megakaryocyte cultured in vitro through a lipofection transfection method, so that the recombinant is integrated with the DNA of the cell; a cell screened by virtue of G418 and containing a positive recombinant is subjected to subculture and enlarged cultivation; a cell which is consistent with the biological properties of an immortalized cell in cellular morphology, cell growth curve, karyotype, nude mice carcinogenicity test, detection of SV40 large T gene in transfection cell DNA, determination of an mRNA expression product and a DNA sequence determination result is screened out as a megakaryocyte model, and is cryopreserved in liquid nitrogen, so as to construct an SV40LT gene-mediated megakaryocyte model and the cell bank of megakaryocyte; therefore, a method for long-term in vitro subculture of the megakaryocyte is established, and the method is applicable to the in vitro research of development, function and pathogenic mechanism of the megakaryocyte.

The present invention provides bio-nanoparticles (BioNPs) for delivering an active agent into hematopoietic stem & progenitor cells (HSPCs). Each BioNP comprises a core and a biological membrane covering the core, which comprises the active agent and a polymer. The biological membrane comprises a phospholipid bilayer and one or more surface proteins of a megakaryocyte (Mk). The active agent remains active after being delivered into the HSPC. Also provided are methods for preparing the BioNPs and uses of the BioNPs for targeted delivery of an active agent into HSPCs and/or treating or preventing a disease or condition in a subject in need thereof.

It has been demonstrated that GABRR1 is expressed on a subset of hematopoietic stem cells (HSC) and megakaryotic progenitor cells (MkP). MkP differentiation and reduction of the number of platelets in blood can be inhibited by inhibiting the GABRR1. GABRR1 overexpression or agonist treatment can significantly promote the generation of MkP and the growth of megakaryocytes.

An object of the present invention is to provide a separation substrate having a high megakaryocyte blocking rate and a high platelet permeation rate, and a cell separation filter and a method for producing a platelet which use the same. The separation substrate of the present invention is a separation substrate including non-woven fabric for separating a platelet from a cell suspension containing a megakaryocyte and the platelet, in which an average pore diameter of the separation substrate is 2.0 μm to 15.0 μm, and a thickness of the separation substrate is 10 μm to 500 μm.